AstraZeneca pays $68.5 million in Seroquel marketing case

Share this article:

Pharmaceutical giant AstraZeneca on Thursday agreed to pay $68.5 million to settle allegations that it inappropriately marketed the drug Seroquel for off-label uses, multiple states' authorities announced.

The settlement will be split among 37 states, making it the largest multi-state settlement from a pharmaceutical company in U.S. history, according to the Bureau of National Affairs. States had charged AstraZeneca with marketing the drug, which is approved to treat schizophrenia and bipolar disorder, for use on elderly patients with dementia, among others. In the lawsuit, states also claimed the company hid the nature of the drug's side effects from healthcare providers.

AstraZeneca has denied any wrongdoing. A company spokesman said that the settlement was paid in order to “bring these matters to a close and move forward with our business of providing medicines to patients.” Last year, the company paid the U.S. a $502 million settlement in a separate case involving the marketing of Seroquel.

Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.